查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854576

肺癌免疫查核點抑制劑市場：依癌症類型、通路、治療方法、最終用戶、作用機制和治療線分類－全球預測（2025-2032年）

Immune Checkpoint Inhibitors for Lung Cancer Market by Cancer Type, Distribution Channel, Treatment Regimen, End User, Mechanism Of Action, Line Of Therapy - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺癌免疫查核點抑制劑市場將成長至 35.5 億美元，複合年成長率為 15.05%。

關鍵市場統計數據
基準年 2024 11.5億美元
預計年份：2025年 13.2億美元
預測年份 2032 35.5億美元
複合年成長率 (%) 15.05%

透過概述臨床進展、相關人員的優先事項和決策需求，為肺癌免疫查核點抑制劑的策略應用奠定基礎。

免疫查核點抑制劑從根本上改變了肺癌的治療模式，使治療策略從單純的細胞毒性療法轉向以靶向免疫調節為核心，旨在產生持久的臨床療效。在過去十年間，臨床醫生和研究人員不斷加深對腫瘤-免疫相互作用的理解，並將這些發現轉化為重新運作抗腫瘤免疫的療法，從而顯著改善了許多患者的生存期和生活品質。

本導言概述了相關人員在評估免疫查核點抑制劑項目時必須考慮的臨床、營運和商業性方面。在臨床方面，整合生物標記檢測、最佳化患者選擇以及最佳化與化療和分子標靶藥物的聯合治療仍然是治療團隊的關鍵考慮因素。在營運方面，生物製藥引入的複雜性會影響醫院和門診的藥物分發方案、低溫運輸物流以及輸注能力規劃。在商業性，與支付方達成一致、產生支持報銷的證據以及基於作用機制和治療線進行差異化定位是推廣策略的核心。

接下來的分析綜合了臨床進展、監管態度和系統層面的壓力，以提供對機會和風險的平衡視角，旨在為決策者提供清晰簡潔的依據，以便優先考慮投資和夥伴關係，從而加速對患者產生有意義的影響。

識別肺癌免疫療法轉型中的轉變，包括生物標記主導的治療、聯合治療以及監管和支付方動態

肺癌免疫治療領域正經歷多重並行且互補的變革，這些變革正在改變治療方法的研發、評估和實施方式。首先，臨床實踐正朝著精準免疫腫瘤學的方向發展，生物標記主導的選擇，例如PD-L1表達和廣泛的基因組特徵，如今已體現在治療方案的選擇和臨床試驗的入組中。因此，試驗設計擴大採用適應性隊列和生物標記富集組，以提高訊號檢測的準確性並加快監管決策。

第二，目前研發的重點是聯合治療透過將查核點抑制劑與化療、分子標靶藥物或其他免疫調節劑合併使用，以解決抗藥性機制並增強療效持久性。此類聯合治療需要新的安全管理模式和新的臨床終點，這將影響監管機構的參與和支付方的證據預期。第三，監管機構和支付者越來越重視真實世界證據和衛生經濟學結果，鼓勵申辦者在傳統的隨機試驗之外，投資於縱向資料收集和結果研究。

第四，生產製造和供應鏈的考量正在推動可擴展生技藥品生產和低溫運輸物流的投資。同時，數位醫療工具和分散式調查方法正在改善患者就醫和留存率，並將潛在的研究對象擴展到傳統學術中心之外。總而言之，這些轉變正在創造一種環境，在這種環境中，臨床策略、數據生成和相關人員參與方面的靈活性將決定哪些治療方法能夠被廣泛採用並為患者帶來切實的益處。

評估美國新關稅政策對2025年肺癌免疫療法供應鏈、臨床計畫和商業性准入的累積影響

影響跨境貿易的政策行動會對藥物研發和商業化生態系統產生連鎖反應，而提案的2025年關稅調整方案為免疫查核點抑制劑計畫帶來了複雜的營運和經濟考量。對進口生物製藥、專用試劑和成品徵收更高的關稅可能會增加產品的單位成本，並迫使製造商重新評估籌資策略和製造外包關係。為此，申辦方可能會加快供應鏈在地化進程，重新談判長期供應商協議，或實現供應商多元化，以降低單一來源風險。

臨床研發極易受到供應中斷和成本波動的影響。關稅上漲導致的臨床供應成本增加以及海關延誤會使臨床試驗物流變得複雜，尤其是在依賴藥物同步運輸的多中心試驗中。申辦者可以透過建立緩衝庫存、認證多個倉庫以及盡可能利用區域生產中心來降低這種風險。同時，隨著支付方對價格上漲的審查日益嚴格，商業性准入策略也可能需要做出調整。

最後，政策環境可以鼓勵策略夥伴關係和垂直整合，促使企業探索本地生產或授權安排，以保障利潤率和供應安全。雖然關稅會增加複雜性，但積極主動的產業計畫、基於情境的財務建模以及與監管機構和海關當局的早期溝通可以減少中斷，並保障患者獲得關鍵免疫療法的機會。

透過基於細分市場的洞察最佳化定位，包括癌症類型、分銷管道、治療方法、機制、治療線和最終用戶。

對肺癌細分的細緻理解對於針對不同肺癌譜系製定個人化的研發和商業化策略至關重要。在同一類肺癌中，非小細胞肺癌和小細胞肺癌之間的差異決定了不同的臨床試驗設計、監管終點和處方模式。在非小細胞肺癌中，非鱗狀細胞癌和鱗狀細胞癌的組織學差異會影響預期療效和安全性。此外，在非鱗狀細胞癌中，腺癌和大細胞癌等亞型可以預測生物標記的出現以及與標靶治療的相互作用。

從醫院藥局到線上藥局、零售藥局和專科藥房，分銷管道的選擇決定了物流模式、病患支援系統和報銷途徑。治療方法分為單藥治療和聯合治療。當聯合治療包含化療或標靶治療時，臨床開發策略必須考慮藥物疊加毒性和治療定序。終端使用者細分，例如門診手術中心、家庭護理機構、醫院和腫瘤診所，會影響設施準備、輸液能力和病患導航服務的設計。

某些藥物，例如Ipilimumab、西米木單抗、Nivolumab、Pembrolizumab、Atezolizumab和Durvalumab，其臨床特徵對於藥物標籤和市場定位至關重要。此外，一線、二線和三線或後續治療方案之間的差異決定了取代現有藥物競爭藥物所需的證據標準。整合這些細分維度，有助於申辦方優先考慮臨床項目、通路策略和證據生成，以滿足不同患者群體和醫療機構的需求。

美洲、歐洲、中東和非洲以及亞太地區的優先事項和差異化採取路徑

臨床實務、監管方式和醫療基礎設施的區域差異顯著影響免疫查核點抑制劑的推廣和應用。在美洲，完善的醫保報銷機制、強大的腫瘤治療網路和健全的臨床試驗能力支持新型療法的快速應用，但成本控制和支付方對療效的審查仍然是需要考慮的因素。該地區的打入市場策略通常結合可靠的III期臨床試驗證據和真實世界研究結果，以確保獲得處方權和有利的用藥政策。

歐洲、中東和非洲的法律規範和支付模式各不相同，因此需要採取細緻入微的方法，充分考慮各國衛生技術評估流程的差異、報銷方案的不同以及物流能力的差異。與區域衛生部門和相關人員合作至關重要，這有助於使臨床證據包與各國的具體價值框架相符。亞太地區的醫療保健體係也多種多樣，既有已開發市場（其應用正在加速推進），也有新興市場（其准入受限和基礎設施不足，需要製定適應性強的分銷和患者援助計劃）。在亞太地區，在地化生產和策略夥伴關係對於提高醫療服務的可負擔性和供應可靠性尤其有效。

在所有地區，如何使實證醫學的產生與當地決策促進因素相契合、如何加大對臨床醫生教育的投入以及如何設計靈活的分發模式都是核心挑戰。跨區域合作能夠充分發揮全球研發的效率，同時又能針對當地監管和支付方環境進行有針對性的調整。

競爭對手和合作夥伴層面的分析表明，創新、夥伴關係和產品組合策略將決定肺癌免疫療法領域的領導地位。

各公司在肺癌免疫療法領域的策略正圍繞著幾個主題：差異化的臨床定位、策略聯盟、產品組合的廣度以及實證醫學能力。優先發展強大的生物標記計畫並與伴隨診斷公司合作的公司，能夠精準觸及臨床定義的、治療獲益最為顯著的亞群患者。投資聯合治療並有效管理早期安全性訊號的公司，則能夠與單藥療法形成顯著的差異化優勢。

從與生物技術創新者進行研究合作，到與標靶藥物生產商達成共同開發契約，策略聯盟得以加速獲取互補療法，並拓展抗藥性疾病的臨床治療選擇。那些在真實世界證據生成、衛生經濟學和結果研究方面建立綜合能力的公司，能夠增強其與支付方的談判籌碼，並促進醫保報銷談判。同時，對可擴展生技藥品生產和地理分散的供應鏈進行投資，可以降低營運風險，並支持更可預測的商業化推廣。

競爭優勢還取決於商業性執行力，領導企業將提供全面的患者援助計劃、治療醫師培訓以及反映價值導向的靈活定價策略。那些將強大的臨床數據、卓越的營運以及與支付方利益相符的提案主張相結合的公司，將更有利於在各種醫療環境中持續獲得認可並長期應用。

為行業領導者提供可操作的建議，以加速免疫療法開發、改善可及性並建立穩健的商業性和臨床路徑

產業領導者可以透過推行一系列切實可行的高優先舉措來加速發展並降低商業化風險。首先，將研發組合與生物標記定義的適應症相匹配，並儘早開發伴隨診斷策略，從而簡化監管流程並最佳化患者篩選。同時，設計包含適應性要素和以病人為中心的有意義終點的聯合試驗，以展現超越傳統生存指標的價值。其次，投資於分散式和混合式試驗模式，以產生更具代表性的真實世界證據，從而擴大應用範圍、提高患者留存率並促進與支付方的對話。

第三，透過供應商多元化、區域化生產選擇和庫存策略來加強供應鏈，進而降低貿易中斷和政策衝擊帶來的風險。第四，積極與支付方溝通，提供透明的價值文件和基於結果的契約，以解決支付方對醫療費用可及性的擔憂，同時保障患者的醫療服務可及性。第五，建立差異化的患者援助計劃，以提高患者的治療依從性，管理免疫相關不利事件，並確保在醫院、腫瘤診所、家庭護理機構和專科藥房之間實現醫療服務的連續性。

最後，與診斷公司、學術中心和受託研究機構建立策略夥伴關係，以加速轉化科學和臨床開發。透過實施這些建議，領導者可以提高產品成功上市、永續取得以及患者療效顯著改善的可能性。

透過嚴謹的調查方法，詳細闡述證據來源、專家參與、三角驗證技術以及局限性，從而打造引人注目的市場情報。

本報告的分析整合了多方面的證據，以確保結論嚴謹可靠。二次研究包括同行評審的臨床文獻、監管指導文件以及公開的臨床試驗註冊庫，旨在闡明治療機制、安全性特徵和試驗設計。為補充這些資訊來源，我們還對腫瘤內科醫生、臨床試驗研究人員、衛生經濟學專家、監管事務專家和供應鏈負責人進行了結構化訪談，以收集經驗見解和營運挑戰。

資料三角測量法將定性訪談結果與已發表的證據聯繫起來，以檢驗新出現的主題並識別公開記錄中的空白。細分分析應用於臨床、分銷和最終用戶維度，以揭示不同的採用路徑。調查方法的局限性包括臨床數據的快速變化、監管時間表的區域差異以及新試驗結果可能改變競爭動態。

在適當情況下，調查方法優先考慮資訊來源選擇和分析假設的透明度，使相關人員能夠評估關鍵發現的來源，並調整方法以進行專注於特定地區、機製或治療方法組合的客製化分析。

本文綜合分析了臨床創新、政策變革和營運重點等面向肺癌免疫治療相關人員的策略意義。

科學創新、策略性商業化策略和不斷變化的政策正在共同重塑免疫查核點抑制劑在肺癌治療中的研發和應用方式。臨床上，生物標記驅動的選擇和聯合治療提高了治療效果，同時也為安全性管理和試驗設計帶來了新的複雜性。在營運上，分銷管道的選擇和終端用戶的接受程度會影響藥物的可及性，而富有韌性的供應鏈對於在政策衝擊下維持治療的連續性至關重要。

從策略角度來看，整合診斷策略、投資可靠的真實世界證據項目並積極與支付方互動的公司將更有利於實現持續的市場推廣。區域差異化需要量身訂做證據方案和實施計劃，以應對不同的監管和報銷環境。綜上所述，這些見解凸顯了在臨床開發、證據產生、生產製造和支付方互動等各個環節進行協調合作對於在該治療領域取得成功的重要性。

最後，不斷發展的免疫療法領域為改善患者預後提供了重要的機會，但要實現這些益處，需要有條不紊的策略、營運韌性以及產業、臨床醫生和醫療保健系統之間的持續合作。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • FDA核准PD-1抑制劑輔助治療早期非小細胞肺癌及其臨床影響
  • 一項真實世界研究凸顯了查核點抑制劑在老年肺癌患者群體中的安全性
  • 開發靶向PD-L1和LAG-3的下一代雙特異性抗體治療轉移性肺腫瘤
  • 整合液態生物檢體生物標記預測非小細胞肺癌患者對免疫查核點抑制劑的反應
  • 評估PD-1/PD-L1療法在肺癌治療中長期存活獲益的新興成本效益模型
  • 擴大度Durvalumab單抗強化治療在不可切除的III期非小細胞肺癌患者中放射線治療後的適應症

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肺癌免疫查核點抑制劑市場（依癌症類型分類）

  • 癌症類型
    • 非小細胞肺癌
      • 非鱗狀
      • 腺癌
      • 大細胞癌
      • 鱗狀上皮
    • 小細胞肺癌

9. 肺癌免疫查核點抑制劑市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第10章：肺癌免疫查核點抑制劑市場（治療方法）

  • 聯合治療
    • 化療
    • 標靶治療
  • 單藥治療

第11章 肺癌免疫查核點抑制劑市場（依最終用戶分類）

  • 門診手術中心
  • 居家照護機構
  • 醫院
  • 腫瘤診所

第12章：肺癌免疫查核點抑制劑市場（依作用機轉分類）

  • CTLA-4抑制劑
    • Ipilimumab
  • PD-1抑制劑
    • 塞米普利單抗
    • Nivolumab
    • Pembrolizumab
  • PD-L1抑制劑
    • Atezolizumab
    • Durvalumab

13. 肺癌免疫查核點抑制劑市場治療線

  • 第一排
  • 第二行
  • 從第三次開始

第14章 肺癌免疫查核點抑制劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 肺癌免疫查核點抑制劑市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國肺癌免疫查核點抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Regeneron Pharmaceuticals, Inc.
    • Pfizer Inc.
    • BeiGene, Ltd.
    • Innovent Biologics, Inc.
    • Shanghai Junshi Biosciences Co., Ltd.
    • Sanofi SA
Product Code: MRR-E40E525C3802

The Immune Checkpoint Inhibitors for Lung Cancer Market is projected to grow by USD 3.55 billion at a CAGR of 15.05% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.15 billion
Estimated Year [2025] USD 1.32 billion
Forecast Year [2032] USD 3.55 billion
CAGR (%) 15.05%

Setting the strategic context for immune checkpoint inhibitors in lung cancer by outlining clinical advances, stakeholder priorities, and decision-making imperatives

Immune checkpoint inhibitors have fundamentally altered the treatment paradigm for lung cancer, moving therapeutic strategy from cytotoxic-only approaches to targeted immune modulation that aims to deliver durable clinical benefit. Over the past decade, clinicians and researchers have advanced our understanding of tumor-immune interactions, translating those discoveries into therapeutics that reinvigorate antitumor immunity and alter survival and quality-of-life considerations for many patients.

This introduction frames the clinical, operational, and commercial dimensions that stakeholders must weigh when evaluating immune checkpoint inhibitor programs. Clinically, integrating biomarker testing, refining patient selection, and optimizing sequencing with chemotherapy and targeted agents remain primary considerations for therapeutic teams. Operationally, the complexity of introducing biologic therapies influences distribution choices, cold-chain logistics, and infusion capacity planning across hospitals and ambulatory settings. Commercially, alignment with payers, evidence generation to support reimbursement, and differentiated positioning based on mechanism of action and line of therapy are central to adoption strategies.

As you read further, the analysis that follows synthesizes clinical progress, regulatory posture, and system-level pressures to present a balanced view of opportunities and risks. The goal is to equip decision-makers with a clear, concise foundation for prioritizing investments and partnerships that will accelerate meaningful patient impact.

Identifying transformative shifts reshaping lung cancer immunotherapy including biomarker-driven care, combination approaches, and regulatory and payer dynamics

The landscape for lung cancer immunotherapy is in the midst of several concurrent and reinforcing shifts that are changing how therapies are developed, evaluated, and delivered. First, clinical practice has moved toward precision immuno-oncology where biomarker-driven selection-such as PD-L1 expression and broader genomic signatures-informs therapeutic choice and trial enrollment. Consequently, trial designs increasingly embed adaptive cohorts and biomarker-enriched arms to improve signal detection and expedite regulatory decision-making.

Second, combination strategies are now a core development focus, pairing checkpoint inhibitors with chemotherapy, targeted agents, or other immune modulators to address resistance mechanisms and enhance response durability. These combinations require new safety management paradigms and novel clinical endpoints, which in turn influence regulatory engagement and payer evidence expectations. Third, regulatory agencies and payers are placing greater emphasis on real-world evidence and health-economic outcomes, prompting sponsors to invest in longitudinal data collection and outcomes research alongside classical randomized trials.

Fourth, manufacturing and supply chain considerations are driving investment in scalable biologics production and cold-chain logistics. At the same time, digital health tools and decentralized trial methodologies are improving patient access and retention, expanding the potential study population beyond traditional academic centers. Taken together, these shifts are creating an environment where agility in clinical strategy, data generation, and stakeholder engagement will determine which therapies achieve broad adoption and meaningful patient benefit.

Assessing the cumulative impact of new United States tariff policies in 2025 on lung cancer immunotherapy supply chains, clinical programs, and commercial access

Policy actions that affect cross-border trade can reverberate across the drug development and commercialization ecosystem, and proposed tariff changes in 2025 present a complex set of operational and economic considerations for immune checkpoint inhibitor programs. Higher duties on imported biologic materials, specialized reagents, or finished products can increase the unit cost of goods, potentially pressuring manufacturers to reevaluate sourcing strategies and contract manufacturing relationships. In response, sponsors may accelerate localization of supply chains, renegotiate long-term supplier agreements, or diversify suppliers to mitigate single-source risks.

Clinical development is sensitive to supply interruptions and cost volatility. Tariff-driven increases in the cost of clinical supplies or delays at customs can complicate trial logistics, particularly for multicenter studies that rely on synchronized drug shipments. Sponsors can mitigate this risk by building buffer inventories, qualifying multiple depots, and leveraging regional manufacturing hubs where feasible. Meanwhile, commercial access strategies may need to adapt as payers scrutinize price increases; transparent communication about cost drivers and evidence of clinical value will be critical to maintaining formulary positions.

Finally, the policy environment can incentivize strategic partnerships and vertical integration, encouraging companies to explore regional production or licensing arrangements that preserve margins and secure supply. While tariffs add a layer of complexity, proactive operational planning, scenario-based financial modeling, and early engagement with regulatory and customs authorities can reduce disruption and preserve patient access to critical immunotherapies.

Decoding segmentation-driven insights across cancer type, distribution channel, treatment regimen, mechanism, line of therapy, and end user to optimize positioning

A fine-grained understanding of segmentation is essential for tailoring development and commercialization approaches across the heterogeneous lung cancer landscape. When considering cancer type, distinctions between Non-Small Cell Lung Cancer and Small Cell Lung Cancer drive different clinical trial designs, regulatory endpoints, and prescribing patterns, while within Non-Small Cell Lung Cancer the split between Non-Squamous and Squamous histologies shapes expected responses and safety profiles. Further subclassification such as Adenocarcinoma and Large Cell Carcinoma under Non-Squamous informs biomarker prevalence and the likely interaction with targeted therapies.

Distribution channel choices-from hospital pharmacy to online pharmacy, retail pharmacy, and specialty pharmacy-determine the logistics model, patient support structures, and reimbursement pathways. The treatment regimen axis separates monotherapy from combination therapy, and when combinations include chemotherapy or targeted therapy the clinical development strategy must address additive toxicities and regimen sequencing. End user segmentation across ambulatory surgical centers, home care settings, hospitals, and oncology clinics influences site readiness, infusion capacity, and the design of patient navigation services.

Mechanism of action segmentation differentiates CTLA-4 inhibitors from PD-1 and PD-L1 inhibitors, with specific agents such as ipilimumab, cemiplimab, nivolumab, pembrolizumab, atezolizumab, and durvalumab offering distinct clinical profiles that matter for labeling and positioning. Finally, line-of-therapy distinctions between first line, second line, and third or later determine the competitive set and the evidence bar required to displace incumbents. Integrating these segmentation dimensions allows sponsors to prioritize clinical programs, channel strategies, and evidence generation to match the needs of distinct patient populations and care settings.

Regional priorities and differentiated adoption trajectories across Americas, Europe, Middle East & Africa, and Asia-Pacific that influence access and commercialization

Regional variation in clinical practice, regulatory approach, and healthcare infrastructure materially affects how immune checkpoint inhibitors are adopted and scaled. In the Americas, established reimbursement pathways, strong oncology networks, and high clinical trial capacity support rapid uptake of novel regimens, though cost containment and payer scrutiny of value remain constant considerations. Market access strategies in this region often combine robust phase III evidence with real-world outcomes to secure formulary placement and favorable utilization policies.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and payer models requires a nuanced approach that accounts for national health technology assessment processes, variable reimbursement timelines, and differing logistical capacities. Engagement with regional health authorities and local stakeholders is essential to align clinical evidence packages with country-specific value frameworks. In Asia-Pacific, the diversity of health systems spans advanced markets with accelerated adoption to emerging markets where access constraints and infrastructure gaps necessitate adaptive distribution and patient support programs. Manufacturing localization and strategic partnerships can be especially impactful in this region to improve affordability and supply reliability.

Across all regions, tailoring evidence generation to local decision drivers, investing in clinician education, and designing flexible distribution models are core imperatives. Cross-regional coordination can unlock efficiencies in global development while allowing targeted adaptations for local regulatory and payer landscapes.

Competitive and collaborative company-level insights revealing where innovation, partnerships, and portfolio strategies will determine leadership in lung cancer immunotherapy

Company strategies in lung cancer immunotherapy are converging around several themes: differentiated clinical positioning, strategic alliances, portfolio breadth, and capabilities in evidence generation. Firms that prioritize robust biomarker programs and companion diagnostic partnerships position themselves to capture clinically defined subpopulations where therapeutic benefit is most pronounced. Companies that invest in combination science and manage early safety signals effectively can create compelling differentiation versus monotherapy options.

Strategic collaborations-ranging from research partnerships with biotechnology innovators to co-development agreements with makers of targeted agents-accelerate access to complementary mechanisms and expand clinical options for resistant disease. Firms that build integrated capabilities in real-world evidence generation, health economics, and outcomes research strengthen payer discussions and facilitate reimbursement negotiations. Meanwhile, investments in scalable biologics manufacturing and geographically diversified supply chains reduce operational risk and can support more predictable commercialization rollouts.

Competitive positioning also rests on commercial execution, with leaders offering comprehensive patient support programs, education for treating physicians, and adaptive pricing strategies that reflect value-based outcomes. Companies that combine strong clinical data with operational excellence and payor-aligned value propositions will be best placed to sustain adoption and long-term utilization across diverse care settings.

Actionable recommendations for industry leaders to accelerate development, enhance access, and build resilient commercial and clinical pathways in immunotherapy

Industry leaders can accelerate progress and de-risk commercialization by pursuing a set of actionable, prioritized initiatives. First, align R&D portfolios with biomarker-defined indications and develop companion diagnostic strategies early to streamline regulatory pathways and improve patient selection. Concurrently, design combination trials that incorporate adaptive elements and meaningful patient-centric endpoints to demonstrate value beyond traditional survival metrics. Second, invest in decentralized and hybrid trial models to broaden recruitment, enhance retention, and generate more representative real-world evidence that supports payer dialogues.

Third, fortify supply chains through supplier diversification, regional manufacturing options, and inventory strategies that reduce exposure to trade disruptions and policy shocks. Fourth, engage payers proactively with transparent value dossiers and outcomes-based contracting where appropriate to address affordability concerns while protecting access. Fifth, build differentiated patient support programs that facilitate adherence, manage immune-related adverse events, and enable treatment continuity across hospitals, oncology clinics, home care settings, and specialty pharmacies.

Finally, cultivate strategic partnerships with diagnostics firms, academic centers, and contract research organizations to accelerate translational science and speed clinical development. By implementing these recommendations, leaders will enhance the likelihood of successful product launches, sustainable access, and measurable improvements in patient outcomes.

Robust research methodology detailing evidence sources, expert engagement, triangulation methods, and limitations used to produce defensible market intelligence

The analysis underpinning this report integrates multiple evidence streams to ensure rigorous, defensible conclusions. Secondary research included peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries to map therapeutic mechanisms, safety profiles, and trial designs. To complement these sources, structured interviews were conducted with oncologists, clinical trial investigators, health economics specialists, regulatory affairs experts, and supply chain leaders to capture experiential insights and operational challenges.

Data triangulation methods linked qualitative interview findings with published evidence to validate emergent themes and identify gaps in the public record. Segmentation analyses were applied to clinical, distribution, and end-user dimensions to illuminate differentiated adoption pathways. Limitations of the methodology include the rapidly evolving nature of clinical data, regional variability in regulatory timelines, and the potential for emerging trial results to alter competitive dynamics; to mitigate these, the study highlights areas for ongoing surveillance and recommends periodic updates to maintain relevance.

Where appropriate, the methodology prioritized transparency in source selection and analytic assumptions, enabling stakeholders to assess the provenance of key findings and to adapt the approach for bespoke analyses focused on particular geographies, mechanisms, or therapeutic combinations.

Concluding synthesis that crystallizes strategic implications from clinical innovation, policy shifts, and operational priorities for lung cancer immunotherapy stakeholders

The convergence of scientific innovation, strategic commercialization tactics, and policy evolution is reshaping how immune checkpoint inhibitors are developed and used in lung cancer care. Clinically, biomarker-driven selection and combination regimens are refining therapeutic benefit while introducing new complexities for safety management and trial design. Operationally, distribution channel choice and end-user readiness influence access, and resilient supply chains are essential to preserve continuity of care in the face of policy shocks.

From a strategic perspective, companies that integrate diagnostic strategies, invest in robust real-world evidence programs, and engage payers proactively will be better positioned to achieve durable adoption. Regional differentiation requires tailored evidence packages and localized execution plans to accommodate varying regulatory and reimbursement landscapes. Collectively, these insights underscore that success in this therapeutic area hinges on coordinated efforts across clinical development, evidence generation, manufacturing, and payer engagement.

In closing, the evolving immunotherapy landscape presents substantial opportunities to improve patient outcomes, but realizing those gains requires disciplined strategy, operational resilience, and sustained collaboration among industry, clinicians, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. FDA approval and clinical impact of adjuvant PD-1 inhibitors in early-stage NSCLC management
  • 5.2. Real-world evidence studies highlighting safety profiles of checkpoint inhibitors in elderly lung cancer cohorts
  • 5.3. Development of next-generation bispecific antibodies targeting PD-L1 and LAG-3 in metastatic lung tumors
  • 5.4. Integration of liquid biopsy biomarkers to predict response to immune checkpoint blockade in NSCLC patients
  • 5.5. Emergence of cost-effectiveness models assessing long-term survival benefits of PD-1/PD-L1 therapies in lung cancer
  • 5.6. Expanding indications for durvalumab consolidation therapy following chemoradiation in stage III unresectable NSCLC

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Cancer Type

  • 8.1. Cancer Type
    • 8.1.1. Non-Small Cell Lung Cancer
      • 8.1.1.1. Non-Squamous
      • 8.1.1.1.1. Adenocarcinoma
      • 8.1.1.1.2. Large Cell Carcinoma
      • 8.1.1.2. Squamous
    • 8.1.2. Small Cell Lung Cancer

9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy
  • 9.4. Specialty Pharmacy

10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. With Chemotherapy
    • 10.1.2. With Targeted Therapy
  • 10.2. Monotherapy

11. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Oncology Clinics

12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Mechanism Of Action

  • 12.1. CTLA-4 Inhibitor
    • 12.1.1. Ipilimumab
  • 12.2. PD-1 Inhibitor
    • 12.2.1. Cemiplimab
    • 12.2.2. Nivolumab
    • 12.2.3. Pembrolizumab
  • 12.3. PD-L1 Inhibitor
    • 12.3.1. Atezolizumab
    • 12.3.2. Durvalumab

13. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line Of Therapy

  • 13.1. First Line
  • 13.2. Second Line
  • 13.3. Third Or Later

14. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immune Checkpoint Inhibitors for Lung Cancer Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immune Checkpoint Inhibitors for Lung Cancer Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Merck & Co., Inc.
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. F. Hoffmann-La Roche Ltd
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. Regeneron Pharmaceuticals, Inc.
    • 17.3.6. Pfizer Inc.
    • 17.3.7. BeiGene, Ltd.
    • 17.3.8. Innovent Biologics, Inc.
    • 17.3.9. Shanghai Junshi Biosciences Co., Ltd.
    • 17.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA IMMU